Australian Doctor Australian Doctor 7th September 2018 | Page 19
FOR TREATMENT IN ASTHMA.
THE DIFFERENCE
IS SYMBICORT
1,2
® * 1–5
budesonide/
formoterol
FAST ONSET AND EFFECTIVE
ASTHMA CONTROL **
*
CHOICE OF DEVICE.
FULL ICS DOSE RANGE.
*
†1–3
1,2,4
‡1,2
^1,2,5
†1–3 minutes onset of LABA component bronchodilation. 1–3
** Significant reduction in time to first severe exacerbation with Symbicort maintenance
and reliever therapy vs. fixed-dose Seretide (fluticasone/salmeterol) plus SABA. 1,2,4
#
®
®
* NO SEPARATE RELIEVER REQUIRED
§1,2
As per Symbicort Maintenance and Reliever Therapy (SMART ™ ). 1,2 No separate reliever is required
when Symbicort is prescribed in the treatment of moderate or severe asthma (as SMART ™ ). 1,2
§
Symbicort for oral inhalation as Turbuhaler
or Rapihaler. 1,2
^ Low, medium and high ICS doses available. 1,2,5
‡
®
®
ICS = inhaled corticosteroid. #Severe exacerbation was defined as deterioration in asthma, resulting in hospitalisation/emergency room treatment, oral steroids for ≥3 days
or an unscheduled visit (i.e. patient-initiated) leading to treatment change. SABA = short-acting beta-agonist; LABA = long-acting beta-agonist.
4
BEFORE PRESCRIBING PLEASE REVIEW PBS AND PRODUCT INFORMATION AVAILABLE IN THE PRIMARY ADVERTISEMENT IN
THIS PUBLICATION OR ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR www.astrazeneca.com.au/PI.
References: 1. Symbicort Turbuhaler Approved Product Information, 19 December 2017. 2. Symbicort Rapihaler Approved Product Information, 28 March 2017. 3. Seberová E et al. Respir Med 2000 Jun; 94(6):607–611. 4. Vogelmeier C et al. Eur Respir J 2005
Nov; 26(5):819–828. 5. http://www.asthmahandbook.org.au/management/adults. Date accessed: 27 April, 2018. Symbicort, Rapihaler and Turbuhaler are registered trademarks and SMART is a trademark of the AstraZeneca group of companies. Seretide is a
registered trademark of GlaxoSmithKline Australia Pty Ltd. Registered user AstraZeneca Pty. Ltd. ABN 54 009 682 311. 66 Talavera Road, Macquarie Park, NSW 2113. www.astrazeneca.com.au. For Medical Information enquiries: 1800 805 342
or [email protected]. To report an adverse event: 1800 805 342 or via https://aereporting.astrazeneca.com. Date of preparation: April 2018. AU-4316. 14796-FP/S.
®
®
®
®
®
®
®
™
®